Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous ofatumumab dose-ranging MRI study in relapsing-remitting multiple sclerosis
NL-OMON39973Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ofatumumab in multiple sclerosis (MS) (4 arms), sponsored by GSK. Primary endpoint: Cumulative number of new T1 gadolinium-enhancing brain lesions over 12 weeks. Started Jan 2012; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON39973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39973.